trending Market Intelligence /marketintelligence/en/news-insights/trending/n7lrspro_56htxddnonz8a2 content esgSubNav
In This List

Regulus pauses clinical activities, reduces workforce to preserve capital

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Regulus pauses clinical activities, reduces workforce to preserve capital

Regulus Therapeutics Inc. said it paused certain clinical activities and will lay off about 60% of its workforce.

The San Diego-based biopharmaceutical company paused recruitment activities for its RG-012, its potential treatment for Alport syndrome. A phase 1 trial of RGLS4326, another kidney disease drug, was paused.

Regulus expects the restructuring to yield over $20 million in annualized savings, extending its cash runway into mid-2019.

"I am very disappointed that we need to take these drastic steps to preserve our capital," company President and CEO Jay Hagan said in a news release.

Regulus is in talks to potentially restructure a partnership with Paris-based Sanofi.